ADC Therapeutics

Overview

ADC Therapeutics is a publicly traded biotechnology company focused on antibody-drug conjugates (ADCs). Its core approved product is ZYNLONTA (loncastuximab tesirine-lpyl), a CD19-directed ADC for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company applies in-house CMC capabilities, a global commercialization footprint, and a PBD-based warhead platform licensed from MedImmune/AstraZeneca.

Core product and mechanism

• ZYNLONTA is a humanized anti-CD19 monoclonal antibody linked via a cathepsin-cleavable linker to SG3199, a pyrrolobenzodiazepine (PBD) dimer cytotoxin.
• Mechanism: binds CD19-expressing cells, internalizes, and releases the PBD warhead that forms irreversible DNA cross-links, leading to cell death. PBD dimers can produce a bystander effect and immunogenic cell death, supporting combination strategies.
• Administration: dosing considerations include a Q3W schedule; monotherapy does not require REMS or inpatient stay.

Product portfolio and pipeline

• ZYNLONTA: approved for 3L+ DLBCL and studied across additional indications and combinations.
• ADCT-241 (PSMA-targeting ADC): IND-enabling activities completed; preclinical development for metastatic castration-resistant prostate cancer; partnership opportunities are being explored.
• LOTIS series:
  • LOTIS-5: Phase 3 confirmatory trial of ZYNLONTA plus rituximab versus immunochemotherapy in relapsed/refractory DLBCL (2L+ focus). Topline data expected H1 2026; full data by end of 2026; potential sBLA in 2027.
  • LOTIS-7: Phase 1b multi-arm study of ZYNLONTA in combination with glofitamab, mosunetuzumab, or polatuzumab vedotin; dose escalation/expansion with two ZYNLONTA dose levels.
  • LOTIS-2: Pivotal Phase 2 in relapsed/refractory DLBCL after ≥2 lines; used for accelerated approvals in multiple regions.
  • LOTIS-10: Phase 1b hepatic impairment study in DLBCL/HGBCL (~56 patients planned).
• Investigator-initiated trials (IITs) and other studies: programs in marginal zone lymphoma (MZL), follicular lymphoma (FL), and pediatric/adolescent B-cell NHL (Glo-BNHL platform trial with a three-arm design including an ADC arm).

Commercialization and global partnerships

• United States: direct commercialization in 3L+ DLBCL with a dedicated field force and cross-functional commercial team; distribution through wholesalers and group purchasing organizations.
• Japan: exclusive license with Mitsubishi Tanabe Pharma Corporation (TPC); TPC completed a Phase 1/2 bridging study and joined LOTIS-5; agreement includes milestone and royalty arrangements.
• Greater China, Singapore, Taiwan, Hong Kong, Macau: joint venture with Overland Pharmaceuticals (Overland ADCT BioPharma) for development and commercialization in the Territory; the company retains an option to co-promote.
• Rest of world (ex-U.S. and ex-Japan): Sobi holds an exclusive license for most territories and will develop and commercialize ZYNLONTA; certain global studies are cost-shared.

Intellectual property and licensing

• Patent portfolio: more than 230 patents issued worldwide with additional pending applications. Typical patent expiration windows range from the early 2030s into the 2040s; product-specific patents for ZYNLONTA extend into that range.
• ADC platform: PBD warhead and linker technology licensed from MedImmune (AstraZeneca). The license covers PBD-based ADCs for a defined set of targets and includes co-owned or licensed patents with exclusive exploitation rights during the license term for certain patents.
• Product IP: ZYNLONTA-related patent families cover target-related matters, dosing, and uses.

Regulatory status and approvals

• United States: FDA accelerated approval for relapsed/refractory DLBCL after two or more lines; post-approval confirmatory trials required.
• European Union: conditional marketing authorization for relapsed/refractory DLBCL after two or more lines.
• China: conditional approval from NMPA (Dec 2024) for relapsed/refractory DLBCL after two or more lines; full approval contingent on confirmatory trial results.
• Canada: Health Canada approval (Mar 2025) for relapsed/refractory DLBCL after two or more lines; contingent on confirmatory trial results.
• The program has received various expedited regulatory designations (Fast Track, Breakthrough, Priority Review, Accelerated Approval) and orphan drug designations where applicable.

Financing and capital structure

• Royalty financing with HealthCare Royalty Partners (HCR): up to $325 million potential; initial proceeds $225 million with an additional $75 million contingent on the first European sale. Royalty obligations include 7% on worldwide net sales outside certain Asian markets for ZYNLONTA and related receipts, with regional and product variations and a royalty cap of 2.50x the investment (2.25x under certain conditions). The agreement was amended (Feb 18, 2026) to replace a buy-out requirement on change of control with a change-of-control payment ($150 million rising to $200 million after Jan 1, 2028). A potential buyout option exists for remaining royalties ($525 million rising to $750 million if after Jan 1, 2029).
• Term loan facility: August 2022 term loans totaling $120 million from lenders including Oaktree and Owl Rock, maturing August 15, 2029. Interest is SOFR + 7.50% (or base rate + 6.50% for the first five years). Loans are secured by company assets and certain subsidiaries and include covenants and minimum cash requirements.
• Partnering and milestone structures:
  • TPC (Japan): $30 million upfront; up to $205 million in milestones; royalties in the high-teens to low-twenties on net sales in Japan.
  • Sobi (ROW): upfront payments in 2022 and 2023 totaling $105 million, up to $332.5 million in milestones, and tiered royalties (mid-teens to mid-twenties), with co-funding for select global studies.
  • Overland ADCT BioPharma (Greater China and specified territories): exclusive development and commercialization license with royalty and equity-like considerations and rights to co-promote on a product-by-product basis.

Manufacturing and operations

• Manufacturing model: outsourced to a network of CMOs with in-house CMC oversight; the company does not operate its own manufacturing facilities.
• Quality and supply chain: the company manages vendor relationships, quality control, and GMP-compliant supply, with external specialists supporting stability testing and other functions.

Market opportunity and competition

• Focused on lymphomas: DLBCL, MZL, FL. DLBCL is the most common lymphoma and represents a substantial market opportunity across 2L and 3L+ segments.
  • U.S. estimates referenced for disease incidence and treated patient subgroups include approximately 32,000 DLBCL diagnoses annually; drug-treated 2L DLBCL ~12,000; 3L+ ~6,000. MZL and FL 5-year prevalence and treated patient estimates were described for planning and market assessment.
• Competitive landscape: includes established biopharma and biotech players active in ADCs, bispecifics, CAR-T, and alternative payload technologies (examples include AbbVie, Daiichi Sankyo, Genmab, GSK, Gilead, J&J, Mersana, Sanofi, Roche, Pfizer, Zymeworks).
• Strategy: LOTIS-5 and LOTIS-7 aim to position ZYNLONTA as a backbone therapy in earlier lines or in combination with established regimens and bispecific antibodies.

Clinical development milestones

• LOTIS-5: randomized Phase 3 in 2L+ DLBCL; topline data expected H1 2026; full data by end of 2026; potential sBLA in 2027 if results support filing.
• LOTIS-2: Phase 2 pivotal program supporting accelerated and conditional approvals.
• LOTIS-7: Phase 1b/2 combinations program in 3L+ and 2L+ DLBCL/HGBCL with glofitamab, mosunetuzumab, and polatuzumab; data expected mid-2026 with broader data outputs through 2026.
• Ongoing IITs and pediatric platform trials expand exploration into indolent lymphomas and pediatric B-cell NHL.
• LOTIS-10: hepatic impairment safety and PK study targeting ~56 patients.

If you want, I can produce a one-page executive summary focused strictly on the core product, pipeline, and partnership milestones, or create a timeline of upcoming regulatory and clinical events.